Merck Insiders Sell US$6.4m Of Stock, Possibly Signalling Caution

Simply Wall StJan 27 22:59

Merck Shares Are Trading Higher After the Company Announced WELIREG Has Gained FDA Priority Review.

BenzingaJan 27 22:50

TD Cowen Adjusts Price Target on Merck to $121 From $140

MT NewswiresJan 27 22:46 · Ratings

Merck's WELIREG Gains FDA Priority Review for Treating Advanced Pheochromocytoma and Paraganglioma

BenzingaJan 27 19:47

Express News | Merck & Co Inc - FDA Sets Pdufa Date of May 26, 2025 for Welireg

BreakingsJan 27 19:45

Express News | FDA Grants Priority Review to Merck’s Application for Welireg® (Belzutifan) for the Treatment of Patients With Advanced Pheochromocytoma and Paraganglioma (Ppgl)

BreakingsJan 27 19:45